BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Sang Hyoung Park, Satimai Aniwan, Edward V Loftus. Advances in the use of biologics and other novel drugs for managing inflammatory bowel diseaseCurrent Opinion in Pharmacology 2017; 37: 65 doi: 10.1016/j.coph.2017.09.007
2
Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from KoreaDigestive Diseases and Sciences 2017; 62(10): 2882 doi: 10.1007/s10620-017-4715-7
3
Gloria S. Z. Tun, Robert Downey, Kerry Robinson, Alison Wright, Laura Marshall, Kristina Emsell, Kirsty Swallow, Graeme Wild, Alenka J. Brooks, Thean S. Chew, Melissa F. Hale, Ravishankar Sargur, Alan J. Lobo. High prevalence of antibodies to infliximab and their relation to clinical outcomes in inflammatory bowel disease patientsGastroHep 2019; 1(5): 214 doi: 10.1002/ygh2.363
4
Sang Hyoung Park, Badr Al-Bawardy, Satimai Aniwan, Sunanda V Kane, Nayantara Coelho-Prabhu, Konstantinos A Papadakis, John B Kisiel, David H Bruining, William A Faubion, Laura E Raffals, Darrell S Pardi, William J Tremaine, Michael C Stephens, Jeanne Tung, Sahil Khanna, Maria Alice V Willrich, Edward V Loftus. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel DiseaseCrohn's & Colitis 360 2019; 1(3) doi: 10.1093/crocol/otz047
5
Luis Eduardo Miani Gomes, Francesca Aparecida Ramos da Silva, Lívia Bitencourt Pascoal, Renato Lazarin Ricci, Guilherme Nogueira, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, João José Fagundes, Raquel Franco Leal. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's DiseaseClinics 2019; 74 doi: 10.6061/clinics/2019/e824